Are natural killer cells superior CAR drivers?

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Klingemann, Hans ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Conkwest Inc ^*  (United States)

Author keywords

Cancer; CAR; NK cells; NK 92 cells; On target off tumor effect; T lymphocytes

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL EXPANSION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; LYMPHOCYTE MIGRATION; NATURAL KILLER CELL; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION;

EID: 84902590288     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28147     Document Type: Article

References (25)

1. Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, Levine BL, Litchman M, Maude SL, Rheingold SR, et al. T Cells engineered with a Chimeric Antigen Receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GvHd in children and adults with relapsed, refractory ALL. Blood 2013; 122:67
2. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, et al. Donorderived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; 122:4129-39; PMID:24055823; http://dx.doi.org/10.1182/blood-2013-08-519413
3. Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21:215-23; PMID:19327974; http://dx.doi.org/10.1016/j.coi.2009.02.009
4. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842
5. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, et al. Anti-CD123 Chimeric Antigen Receptor T cells (CART-123) provide a novel myeloablative conditioning regimen that eradicates human acute myeloid leukemia in preclinical models. Blood 2013; 122:143
6. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24
7. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010; 70:9053-61; PMID:20926399; http://dx.doi.org/10.1158/0008-5472.CAN-10-2880
8. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. PLoS One 2007; 2:e326; PMID:17389917; http://dx.doi.org/10.1371/journal.pone.0000326
9. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69:4010-7; PMID:19383914; http://dx.doi.org/10.1158/0008-5472.CAN-08-3712
10. Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009; 33:1255-9; PMID:19147228; http://dx.doi.org/10.1016/j.leukres.2008.11.024
11. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100:1265-73; PMID:12149207
12. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, Wolfraim LA, Fujisaki H, Campana D, Chopas N, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatorycompliant non-viral method. Cancer Gene Ther 2010; 17:147-54; PMID:19745843; http://dx.doi.org/10.1038/cgt.2009.61
13. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui C-H, Geiger TL, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18:676-84; PMID:14961035; http://dx.doi.org/10.1038/sj.leu.2403302
14. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, Leung W, Campana D. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 2012; 14:830-40; PMID:22458956; http://dx.doi.org/10.3109/14653249.2012.671519
15. Romanski A, Uherek C, Bug G, Muller T, Rossig C, Kampfmann M, Krossok N, Hoelzer D, Seifried E, Wels W, et al. Re-targeting of an NK cell line (NK-92) with specificity for CD19 efficiently kills human B-precursor leukemic cells. Blood 2004; 104:751a
16. Chu Y, Yahr A, Ayello J, van de Ven C, Zhou X, Cairo MS. Anti-CD20 Chimeric Antigen Receptor (CAR) modified expanded Natural Killer (NK) cells significantly mediate Burkitt Lymphoma (BL) regression and improve survival in human BL xenografted NSG mice. Blood 2013; 122:3263
17. Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2:e26527; PMID:24404423; http://dx.doi.org/10.4161/onci.26527
18. Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008; 57:411-23; PMID:17717662; http://dx.doi.org/10.1007/s00262-007-0383-3
19. Yang S, Xin A, Brown RD, Ho J, Gibson J, Joshua DE, Wels W, Sze, DM. Development of retargeted CD38-specific NK-92 cell line for potential antimyeloma immunotherapy. [abstr]. Blood 2005; 106:5104
20. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, Kiessling R, Blankenstein T, Abken H, Charo J. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A 2008; 105:17481-6; PMID:18987320; http://dx.doi.org/10.1073/pnas.0804788105
21. Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 2012; 16:569-81; PMID:21595822; http://dx.doi.org/10.1111/j.1582-4934.2011.01343.x
22. Sahm C, Schönfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 2012; 61:1451-61; PMID:22310931; http://dx.doi.org/10.1007/s00262-012-1212-x
23. Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3Cspecific chimeric antigen receptor. Cancer Gene Ther 2012; 19:84-100; PMID:21979579; http://dx.doi.org/10.1038/cgt.2011.66
24. Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2013; (Forthcoming); PMID:24067492; http://dx.doi.org/10.1038/leu.2013.279
25. Koehne G, Guo HF, Trivedi D, Williams RY, O'Reilly RO, Cheung V. Redirecting NK-cell cytolytic activity to solid tumors using chimeric scFv receptor genemodified adoptive immunotherapy. ASCO Proc 2001; 22: 175a.